leisure time -WSS

leisure time

author：explore 2025-09-29 01:07:05 - browse：7

A new asthma treatment that could be administered just once every six months has succeeded in two Phase 3 trials, developer GlaxoSmithKline announced Tuesday.

The drug, depemokimab, is designed to treat asthma by targeting a protein called interleukin-5, or IL-5. The protein is linked to the type of inflammation found in most severe asthma cases, according to the pharma company.

Depemokimab hit its primary endpoints in the trials, reducing asthma attacks over a year’s time frame. The company didn’t disclose exact details from the SWIFT-1 and SWIFT-2 trials.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Couple fighting to bring baby home from Mexico are finally reunited

WSS

Stanford president's case begs question: Who takes blame?

Seattle police shoot person suspected in downtown stabbing

Lindsay Lohan welcomes 1st child with husband Bader Shammas

Stanford updates investigation of president’s past research

Stanford president faces new allegations over 1999 paper

Couple fighting to bring baby home from Mexico are finally reunited

explore

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Hepatitis C has a cure — but many Americans still lack access to it

Indian pharmaceutical industry in denial over drug

Apple is now the first public company to be valued at $3 trillion

Gilgo Beach murders: What questions remain following Rex Heuermann's arrest?

The high cost of giving birth even with insurance

EF3 tornado rips through North Carolina amid extreme weather nationwide

Jerome Adams on the need for new antivirals for Covid

Why the Crimean Bridge is key to Russia's war in Ukraine

Medical records are filled with copy

Medical experts are missing from AI regulatory conversations

Wikipedia

Why some people catch Covid but never get sick

'Reaching a detente': STAT's Helen Branswell on covering Covid

Actors' union, Hollywood studios squabble over which side to blame as strike enters 5th day

Driven by the pandemic, applicants flood public health schools

Why the Crimean Bridge is key to Russia's war in Ukraine

Judge rejects Trump's request to move Stormy Daniels hush

knowledge

focus

knowledge

hotspot